News & Media

Recent updates from Arcutis.

July 9, 2024 Featured

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

December 15, 2023 Featured

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

October 6, 2023 Featured

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

February 18, 2025

Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

February 5, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 4, 2025

Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a “Clear Win for Your Skin”

January 27, 2025

Arcutis to Present at the Guggenheim SMID Cap Biotech Conference

January 12, 2025

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

January 6, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 16, 2024

Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

December 6, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 3, 2024

Arcutis Announces Promotions on Executive Management Team

November 13, 2024

Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

November 6, 2024

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

November 4, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download